Integrating sequential immunotherapy to lung cancer treatment plans


June 24, 2022

1 min watch


Healio Interviews

Marmarelis reports holding stock and other ownership interests in Bluebird Bio, Gilead Sciences, Johnson & Johnson, Merck, Pfizer and Portola Pharmaceuticals; receiving honoraria from AstraZeneca, Blueprint Medicines, Health Advances, Janssen Oncology, Novocure, Takeda and Targeted Oncology; serving in a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Celgene and Ikena Oncology; receiving research funding to Marmarelis’s institution from AstraZeneca, Lilly and Trizell; receiving travel, accommodations and expenses from Boehringer Ingelheim and Novocure; and having another relationship with Novartis.

We were unable to process your request. Please try again later. If you continue to have this issue please contact

In this video, Melina Marmarelis, MD, highlights findings from a Lung-MAP nonmatched substudy presented at ASCO Annual Meeting.

“The idea of sequential immunotherapy is something that we’re all grappling with in this era of multiple different immunotherapies approved in different lines,” Marmarelis, assistant professor of medicine at University of Pennsylvania, said.


  • Reckamp KL, et al. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *